홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
CASI
#3957
CASI Pharmaceuticals, Inc. Ordinary Shares
0.2
1
-73.75%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-73.75%
월간 변동
-78.79%
6달 변화
-90.41%
년간 변동율
-91.36%
이전 종가
0.8
0
Open
0.2
1
Bid
Ask
Low
0.2
1
High
0.2
1
양
17
마켓
주식
헬스케어
CASI
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
15.49 M
—
Valuation ratios
Enterprise value
30.34 M
—
Price to earnings ratio
-1.11
—
Price to sales ratio
—
—
Price to cash flow ratio
-1.49
—
Price to book ratio
23.45
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
0.51
—
Return on equity %
14.92
—
Return on invested capital %
-12.38
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
0.94
—
Current ratio
1.09
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
0.35
—
Long term debt to total equity ratio
10.21
—
Per share metrics
Operating cash flow per share
1.91
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
0.99
—
Net current asset value per share
2.58
—
Tangible book value per share
0.11
—
Working capital per share
0.2
—
Book value per share
0.12
—
뉴스
What Drove CASI Pharmaceuticals' 24% Rise After Hours? - CASI Pharmaceuticals (NASDAQ:CASI)
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%
CASI 제약, 나스닥 상장 폐지 통보에 주가 급락
CASI Pharmaceuticals stock plunges on Nasdaq delisting notice
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection
CASI Pharmaceuticals, 나스닥 상장 연장 승인 후 주가 급등
카스, 나스닥 상장 유지 기한 2026년 2월까지 연장
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026
CASI Pharmaceuticals secures $20 million funding for transplant rejection study